Business
PureTech Appoints Robert Lyne as CEO
PureTech Health plc has appointed Robert Lyne as Chief Executive Officer, effective immediately, following his tenure as Interim CEO since July 2025. The company's immediate focus is on securing funding for its new entity, Celea Therapeutics, with an expected close in the first half of 2026, after which PureTech's operational run rate will significantly reduce. Concurrently, PureTech is pursuing financing for Gallop Oncology in 2026. The company plans to operate with a streamlined structure and reduced overhead, adopting a disciplined investment posture to improve return on capital and preserve capital. Following Celea's financing, PureTech will evaluate strategies for shareholder value, potentially including capital returns. Disclaimer*
About this update from Puretech Health Plc
[{"type":"text","content":"\n\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED\n \n18 December 2025\nPureTech Health plc\n \nPureTech Appoints Robert Lyne as Chief Executive Officer\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately.\n \nRobert Lyne commented: \"I'm honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I've seen first-hand the strength of our programs, the talent of our team, and the power of our differentiated model. I'm keen to build on this foundation, working closely with the Board to drive the next phase of execution as we advance transformative therapies for patients and deliver long-term value for our shareholders.\n \n\"Our immediate focus is on securing the funding needed to advance our newest Founded Entity, Celea Therapeutics, following the successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration. This process is progressing, and we expect to close within the first half of 2026, after which PureTech's operational run rate will reduce significantly. In parallel, we are also actively pursuing financing in 2026 for Gallop Oncology, as the strong initial topline data continue to mature, and the program advances to the next stage of development.\n \n\"Going forward, we intend to operate with a streamlined structure and significantly reduced overhead. This will be combined with a disciplined investment posture, pursuing focused innovation initiatives that can be advanced to key inflection points with relatively modest spend to improve our return on capital. Once Celea is fully financed, we expect to evaluate the most effective means of delivering value to shareholders, including potential capital returns, as part of an integrated strategy that continues targeted and impactful innovation. In the meantime, our priority is preserving capital, mai...